EUVIMEDEUVIMED entdecken
Crossref

Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis

Busra Dincer iD, Gizem Yildiztekin, Irfan Cinar

Chemistry & Biodiversity · 2023

DOI: 10.1002/cbdv.202301093 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemistry & Biodiversity, 2023. Verfasst von Busra Dincer und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology, Faculty of Pharmacy, Ondokuz Mayıs University, Samsun, 55100, Turkey. Hauptthemen laut MEDLINE: Paclitaxel, Acetamides, Receptor, Melatonin, MT1, Breast Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 105 Literaturangaben. Gefördert von: Research Fund of the Erzincan Binali Yıldırım University, Turkey.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigates the potential of agomelatine (AGO), a synthetic melatoninergic drug, in combination with paclitaxel (PTX) for the treatment of breast cancer. The effects of AGO, PTX and melatonin (MTN) on breast cancer cell viability were investigated, focusing on the role of MT1 receptors. Cell viability and gene expression were analyzed in MCF‐7 and MDA‐MB‐231 breast cancer cell experiments. The results show that AGO has cytotoxic effects on breast cancer cells similar to MTN. Combining AGO and MTN with PTX showed synergistic effects in MCF‐7 cells. The study also reveals differences in the molecular mechanisms of breast cancer between estrogen‐positive MCF‐7 cells and estrogen‐negative MDA‐MB‐231 cells. Combination with AGO and PTX affects apoptosis‐associated proteins in both cell types. The findings suggest that AGO, combined with PTX, may be a promising adjuvant therapy for breast cancer and highlight the importance of MTN receptors in its mechanism of action.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PaclitaxelAcetamidesReceptor, Melatonin, MT1Breast NeoplasmsEstrogen Receptor alphaAntineoplastic Agents, PhytogenicAntineoplastic AgentsHumansDrug SynergismCell SurvivalFemaleDrug Screening Assays, AntitumorCell ProliferationApoptosisMelatoninCell Line, TumorDose-Response Relationship, DrugMCF-7 CellsNaphthalenes

Stichwörter der Autor:innen

antitumor agentscancergene expressionmedicinal chemistry

Substanzen

PaclitaxelAcetamidesReceptor, Melatonin, MT1agomelatineEstrogen Receptor alphaMelatoninAntineoplastic Agents, PhytogenicESR1 protein, humanAntineoplastic AgentsNaphthalenes

Autor:innen und Institutionen

  • Department of Pharmacology, Faculty of Pharmacy, Ondokuz Mayıs University, Samsun, 55100, Turkey.
  • Department of Pharmaceutical Toxicology, Faculty of Pharmacy, Erzincan Binali Yildirim University, Erzincan, 24100, Turkey.
  • Department of Pharmacology, Faculty of Medicine, Kastamonu University, Kastamonu, 37150, Turkey.

ORCID-Profile: Busra Dincer

Förderung

  • Research Fund of the Erzincan Binali Yıldırım University, Turkey

Zitieren

APA

Dincer, B., Yildiztekin, G., & Cinar, I. (2023). Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis. Chemistry & Biodiversity. https://doi.org/10.1002/cbdv.202301093

Vancouver

Dincer B, Yildiztekin G, Cinar I. Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis. Chemistry & Biodiversity. 2023. doi:10.1002/cbdv.202301093

BibTeX
@article{Dincer2023,
  author = {Dincer, Busra and Yildiztekin, Gizem and Cinar, Irfan},
  title = {Unlocking Synergistic Potential: Agomelatine Enhances the Chemotherapeutic Effect of Paclitaxel in Breast Cancer Cell Through MT1 Melatonin Receptors and ER‐alpha Axis},
  journal = {Chemistry & Biodiversity},
  year = {2023},
  doi = {10.1002/cbdv.202301093}
}
Kostenlos starten →